NSCLC and CRC, Oncology
Conditions
Brief summary
Incidence of Dose Limiting Toxicities, Adverse Events, Serious Adverse Events, Adverse Events leading to discontinuation, and deaths., Overall Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR).
Detailed description
Summary measures of BMS-986466 PK parameters in plasma including Maximum concentration (Cmax), Time to maximum concentration (Tmax), and Area Under the Curve (AUC(0-T)) from concentration-time data., Progression Free Survival (PFS), Disease Control Rate (DCR), Duration of Response (DOR), and Time To Response (TTR) per RECIST v1.1 by BICR., Incidence of Dose Limiting Toxicities, Adverse Events, Serious Adverse Events, Adverse Events leading to discontinuation, and deaths., Summery measures of target engagement (ability of a drug to bind to a specific molecule)
Interventions
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Dose Limiting Toxicities, Adverse Events, Serious Adverse Events, Adverse Events leading to discontinuation, and deaths., Overall Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Summary measures of BMS-986466 PK parameters in plasma including Maximum concentration (Cmax), Time to maximum concentration (Tmax), and Area Under the Curve (AUC(0-T)) from concentration-time data., Progression Free Survival (PFS), Disease Control Rate (DCR), Duration of Response (DOR), and Time To Response (TTR) per RECIST v1.1 by BICR., Incidence of Dose Limiting Toxicities, Adverse Events, Serious Adverse Events, Adverse Events leading to discontinuation, and deaths., Summery measures of target engagement (ability of a drug to bind to a specific molecule) | — |
Countries
Belgium, Finland, France, Italy, Spain
Outcome results
None listed